GlassScriptPhysician profile
Michael J Toole
NPI 1396008918
$27,064.73
in general payments reported to CMS, 2019-2025
49 companies · $572 in 2025
The $572 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $10K · 2021: $2,047 · 2022: $2,390 · 2023: $377 · 2024: $410 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,359.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $9,716.16 | 2019-2023 | Rezlidhia, Tavalisse |
| Astrazeneca Pharmaceuticals LP | $2,541.29 | 2019-2020 | |
| Beigene, LTD. | $2,475.00 | 2020 | |
| Stemline Therapeutics INC. | $2,100.00 | 2022 | |
| Seagen INC. | $1,470.00 | 2020 | |
| Morphosys, US INC. | $1,140.00 | 2021 | |
| Kite Pharma, INC. | $1,103.50 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $797.52 | 2019-2025 | Opdualag, Opdivo |
| Janssen Pharmaceuticals, INC | $730.36 | 2019-2021 | |
| Beigene USA, INC. | $720.38 | 2020-2023 | Brukinsa |
| Janssen Biotech, INC. | $488.02 | 2019-2024 | Erleada |
| Takeda Pharmaceuticals U.S.A., INC. | $334.43 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $310.94 | 2019-2023 | Imbruvica |
| Merck Sharp & Dohme LLC | $297.69 | 2019-2025 | Keytruda, Keytruda Qlex |
| Amgen INC. | $270.06 | 2019-2023 | Kyprolis |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Toole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.